Cadrenal Accounts Payable from 2010 to 2025
| CVKD Stock | 19.24 0.13 0.67% |
Accounts Payable | First Reported 2010-12-31 | Previous Quarter 1.5 M | Current Value 760.7 K | Quarterly Volatility 293.9 K |
Check Cadrenal Therapeutics, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cadrenal Therapeutics,'s main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.8 K, Interest Expense of 0.0 or Other Operating Expenses of 5.7 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 2.49. Cadrenal financial statements analysis is a perfect complement when working with Cadrenal Therapeutics, Valuation or Volatility modules.
Cadrenal |
Latest Cadrenal Therapeutics,'s Accounts Payable Growth Pattern
Below is the plot of the Accounts Payable of Cadrenal Therapeutics, Common over the last few years. An accounting item on the balance sheet that represents Cadrenal Therapeutics, obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Cadrenal Therapeutics, are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. Cadrenal Therapeutics,'s Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cadrenal Therapeutics,'s overall financial position and show how it may be relating to other accounts over time.
| Accounts Payable | 10 Years Trend |
|
Accounts Payable |
| Timeline |
Cadrenal Accounts Payable Regression Statistics
| Arithmetic Mean | 480,885 | |
| Geometric Mean | 432,579 | |
| Coefficient Of Variation | 61.11 | |
| Mean Deviation | 162,677 | |
| Median | 404,897 | |
| Standard Deviation | 293,862 | |
| Sample Variance | 86.4B | |
| Range | 1.3M | |
| R-Value | 0.40 | |
| Mean Square Error | 77.4B | |
| R-Squared | 0.16 | |
| Significance | 0.12 | |
| Slope | 24,989 | |
| Total Sum of Squares | 1.3T |
Cadrenal Accounts Payable History
About Cadrenal Therapeutics, Financial Statements
Cadrenal Therapeutics, stakeholders use historical fundamental indicators, such as Cadrenal Therapeutics,'s Accounts Payable, to determine how well the company is positioned to perform in the future. Although Cadrenal Therapeutics, investors may analyze each financial statement separately, they are all interrelated. For example, changes in Cadrenal Therapeutics,'s assets and liabilities are reflected in the revenues and expenses on Cadrenal Therapeutics,'s income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Cadrenal Therapeutics, Common. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Accounts Payable | 1.5 M | 760.7 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out the analysis of Cadrenal Therapeutics, Correlation against competitors. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cadrenal Therapeutics,. If investors know Cadrenal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cadrenal Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Cadrenal Therapeutics, is measured differently than its book value, which is the value of Cadrenal that is recorded on the company's balance sheet. Investors also form their own opinion of Cadrenal Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Cadrenal Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cadrenal Therapeutics,'s market value can be influenced by many factors that don't directly affect Cadrenal Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cadrenal Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Cadrenal Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cadrenal Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.